1
|
The Tumorigenic Role of Circular RNA-MicroRNA Axis in Cancer. Int J Mol Sci 2023; 24:ijms24033050. [PMID: 36769372 PMCID: PMC9917898 DOI: 10.3390/ijms24033050] [Citation(s) in RCA: 9] [Impact Index Per Article: 9.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/28/2022] [Revised: 01/30/2023] [Accepted: 02/02/2023] [Indexed: 02/09/2023] Open
Abstract
Circular RNAs (circRNAs) are a class of endogenous RNAs that control gene expression at the transcriptional and post-transcriptional levels. Recent studies have increasingly demonstrated that circRNAs act as novel diagnostic biomarkers and promising therapeutic targets for numerous cancer types by interacting with other non-coding RNAs such as microRNAs (miRNAs). The miRNAs are presented as crucial risk factors and regulatory elements in cancer by regulating the expression of their target genes. Some miRNAs are derived from transposable elements (MDTEs) that can transfer their location to another region of the genome. Genetic interactions between miRNAs and circular RNAs can form complex regulatory networks with various carcinogenic processes that play critical roles in tumorigenesis and cancer progression. This review focuses on the biological regulation of the correlative axis among circular RNAs, miRNAs, and their target genes in various cancer types and suggests the biological importance of MDTEs interacting with oncogenic or tumor-suppressive circRNAs in tumor progression.
Collapse
|
2
|
van Dooijeweert C, van Diest PJ, Ellis IO. Grading of invasive breast carcinoma: the way forward. Virchows Arch 2021; 480:33-43. [PMID: 34196797 PMCID: PMC8983621 DOI: 10.1007/s00428-021-03141-2] [Citation(s) in RCA: 26] [Impact Index Per Article: 8.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/03/2021] [Revised: 06/03/2021] [Accepted: 06/10/2021] [Indexed: 12/12/2022]
Abstract
Histologic grading has been a simple and inexpensive method to assess tumor behavior and prognosis of invasive breast cancer grading, thereby identifying patients at risk for adverse outcomes, who may be eligible for (neo)adjuvant therapies. Histologic grading needs to be performed accurately, on properly fixed specimens, and by adequately trained dedicated pathologists that take the time to diligently follow the protocol methodology. In this paper, we review the history of histologic grading, describe the basics of grading, review prognostic value and reproducibility issues, compare performance of grading to gene expression profiles, and discuss how to move forward to improve reproducibility of grading by training, feedback and artificial intelligence algorithms, and special stains to better recognize mitoses. We conclude that histologic grading, when adequately carried out, remains to be of important prognostic value in breast cancer patients.
Collapse
Affiliation(s)
- C van Dooijeweert
- Department of Pathology, University Medical Center Utrecht, Utrecht, Netherlands.,Department of Internal Medicine, Meander Medical Center, Amersfoort, Netherlands
| | - P J van Diest
- Department of Pathology, University Medical Center Utrecht, Utrecht, Netherlands.
| | - I O Ellis
- Department of Histopathology, Nottingham University Hospitals, Nottingham, UK
| |
Collapse
|
3
|
Abstract
A type of evolutionarily conserved, noncoding, small, endogenous, single-stranded RNA, miRNAs are widely distributed in eukaryotes, where they participate in various biological processes as critical regulatory molecules. miR-1299 has mainly been investigated in cancers. miR-1299 is a tumor suppressor that regulates the expression of its target genes, activating or inhibiting the transcription of genes regulating biological activities including cell proliferation, migration, survival and programmed cell death. miR-1299 has become a hotspot in research of disease mechanisms and biomarkers; elucidation of the regulatory roles of miR-1299 in tumorigenesis, proliferation, apoptosis, invasion, migration and angiogenesis may provide a new perspective for understanding its biological functions as a tumor suppressor. As key regulatory molecules, microRNAs participate in various biological processes and have become a widespread research focus. This article discusses how the microRNA miR-1299 plays a role as a tumor suppressor and participates in the regulation of tumor pathogenesis. We provide an overview of the role of miR-1299 in tumor diseases and discuss the pathogenesis and regulation mechanisms of miR-1299 in different specific cancers.
Collapse
Affiliation(s)
- Deng Kaiyuan
- Department of Laboratory Medicine, The Second Affiliated Hospital of Harbin Medical University, 150086, China
| | - Huang Lijuan
- Department of Laboratory Medicine, The Second Affiliated Hospital of Harbin Medical University, 150086, China
| | - Sun Xueyuan
- Department of Laboratory Medicine, The Second Affiliated Hospital of Harbin Medical University, 150086, China
| | - Zang Yunhui
- Department of Laboratory Medicine, The Second Affiliated Hospital of Harbin Medical University, 150086, China
| |
Collapse
|
4
|
Allan J, Locke M, Wagener J. Ethnic variability in
post‐mastectomy
breast reconstruction in Counties Manukau District Health Board in 2017: a retrospective review. ANZ J Surg 2020; 90:1402-1407. [DOI: 10.1111/ans.15894] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/13/2019] [Revised: 03/17/2020] [Accepted: 03/23/2020] [Indexed: 11/30/2022]
Affiliation(s)
- Jessica Allan
- Faculty of Medicine and Health ScienceThe University of Auckland Auckland New Zealand
| | - Michelle Locke
- Faculty of Medicine and Health ScienceThe University of Auckland Auckland New Zealand
- Department of Plastic and Reconstructive SurgeryMiddlemore Hospital Auckland New Zealand
| | - Jenny Wagener
- Department of General SurgeryMiddlemore Hospital Auckland New Zealand
| |
Collapse
|
5
|
van Dooijeweert C, van Diest PJ, Baas IO, van der Wall E, Deckers IA. Variation in breast cancer grading: the effect of creating awareness through laboratory-specific and pathologist-specific feedback reports in 16 734 patients with breast cancer. J Clin Pathol 2020; 73:793-799. [PMID: 32276993 DOI: 10.1136/jclinpath-2019-206362] [Citation(s) in RCA: 9] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/04/2019] [Revised: 03/02/2020] [Accepted: 03/29/2020] [Indexed: 12/27/2022]
Abstract
AIMS Histological grade is widely used to guide the management of invasive breast cancer (IBC). Yet, substantial interlaboratory and intralaboratory grading variations exist in daily pathology practice. To create awareness and to facilitate quality improvement, feedback reports, containing case-mix-adjusted laboratory-specific grades benchmarked against other laboratories, were sent to the individual laboratories by 1 March 2018. We studied the effect of these feedback reports on interlaboratory grading variation up till 1 year later. METHODS Overall, 17 102 synoptic pathology reports of IBC resection specimens from 33 laboratories, obtained between 1 March 2017 and 1 March 2019 were retrieved from the Dutch Pathology Registry (PALGA). An overall deviation score (ODS), representing the sum of deviations from the grade-specific overall proportions, was calculated to compare the absolute deviation for all grades at once. Case-mix correction was performed by two multivariable logistic regression analyses, providing laboratory-specific ORs for high-grade versus low-grade IBC. RESULTS After feedback, the overall range between laboratories decreased by 3.8%, 6.4% and 6.6% for grades I, II and III, respectively. Though the mean ODS remained similar (13.8% vs 13.7%), the maximum ODS decreased from 34.1% to 29.4%. The range of laboratory-specific ORs decreased by 21.9% for grade III versus grades I-II. CONCLUSIONS An encouraging decrease in grading variation of IBC was observed after laboratory-specific feedback. Nevertheless, the overall grading variation remains substantial. In view of the important role of grading in patient management, it is adamant that not only feedback should be provided on a regular basis but also other interventions, such as additional training, are required.
Collapse
Affiliation(s)
| | - Paul J van Diest
- Department of Pathology, University Medical Center Utrecht, Utrecht, The Netherlands
| | - Inge O Baas
- Department of Medical Oncology, University Medical Center Utrecht, Utrecht, The Netherlands
| | - Elsken van der Wall
- Department of Medical Oncology, University Medical Center Utrecht, Utrecht, The Netherlands
| | - Ivette A Deckers
- Foundation PALGA (the nationwide network and registry of histopathology and cytopathology in the Netherlands), Houten, The Netherlands
| |
Collapse
|
6
|
van Dooijeweert C, van Diest PJ, Willems SM, Kuijpers CCHJ, van der Wall E, Overbeek LIH, Deckers IAG. Significant inter- and intra-laboratory variation in grading of invasive breast cancer: A nationwide study of 33,043 patients in the Netherlands. Int J Cancer 2020; 146:769-780. [PMID: 30977119 PMCID: PMC6916412 DOI: 10.1002/ijc.32330] [Citation(s) in RCA: 31] [Impact Index Per Article: 7.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/22/2019] [Accepted: 03/28/2019] [Indexed: 12/18/2022]
Abstract
Accurate, consistent and reproducible grading by pathologists is of key-importance for identification of individual patients with invasive breast cancer (IBC) that will or will not benefit from adjuvant systemic treatment. We studied the laboratory-specific grading variation using nationwide real-life data to create insight and awareness in grading variation. Synoptic pathology reports of all IBC resection-specimens, obtained between 2013 and 2016, were retrieved from the nationwide Dutch Pathology Registry (PALGA). Absolute differences in laboratory-proportions of Grades I-III were compared to the national reference. Multivariable logistic regression provided laboratory-specific odds ratios (ORs) for high- vs. low-grade IBC. 33,792 IBC pathology reports of 33,043 patients from 39 laboratories were included, of which 28.1% were reported as Grade I (range between laboratories 16.3-43.3%), 47.6% as Grade II (38.4-57.8%), and 24.3% as Grade III (15.5-34.3%). Based on national guidelines, the indication for adjuvant chemotherapy was dependent on histologic grade in 29.9% of patients. After case-mix correction, 20 laboratories (51.3%) showed a significantly deviant OR. Significant grading differences were also observed among pathologists within laboratories. In this cohort of 33,043 breast cancer patients, we observed substantial inter- and intra-laboratory variation in histologic grading. It can be anticipated that this has influenced outcome including exposure to unnecessary toxicity, since choice of adjuvant chemotherapy was dependent on grade in nearly a third of patients. Better standardization and training seems warranted.
Collapse
Affiliation(s)
| | - Paul J. van Diest
- Department of PathologyUniversity Medical Center UtrechtUtrechtThe Netherlands
| | - Stefan M. Willems
- Department of PathologyUniversity Medical Center UtrechtUtrechtThe Netherlands
| | | | - Elsken van der Wall
- Department of Medical OncologyUniversity Medical Center UtrechtUtrechtThe Netherlands
| | - Lucy I. H. Overbeek
- Foundation PALGA (the nationwide network and registry of histo‐ and cytopathology in The Netherlands)HoutenThe Netherlands
| | - Ivette A. G. Deckers
- Foundation PALGA (the nationwide network and registry of histo‐ and cytopathology in The Netherlands)HoutenThe Netherlands
| |
Collapse
|
7
|
Zhao W, Dong M, Pan J, Wang Y, Zhou J, Ma J, Liu S. Circular RNAs: A novel target among non‑coding RNAs with potential roles in malignant tumors (Review). Mol Med Rep 2019; 20:3463-3474. [PMID: 31485661 PMCID: PMC6755165 DOI: 10.3892/mmr.2019.10637] [Citation(s) in RCA: 23] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/02/2019] [Accepted: 06/24/2019] [Indexed: 12/20/2022] Open
Abstract
Circular RNAs (circRNAs) are a class of non-coding RNAs that are generated via alternative back-splicing, which connects the terminal 5′ and 3′ends. Due to their unique loop structure, circRNAs are resistant to ribonucleases and more stable than linear RNAs. In vivo, they are usually highly conserved and stably expressed in tissue/developmental-stage-specific manners. Generally, circRNAs function as microRNA sponges and splicing regulators, as well as in protein binding and transcription. Some circRNAs contain open reading frames with internal ribosomal entry site elements and can thus encode specific proteins. Previously, circRNAs were thought to be erroneous splicing products or by-products of mRNA splicing. With the development of the next-generation sequencing techniques, it has become increasingly clear that circRNAs are abundantly widespread in eukaryotes and that they play significant roles in malignant tumor progression. The present review briefly introduces the biogenesis and functions of circRNAs, as well as summarizes recent research in several common malignancies. The present review also addresses the prospects of circRNAs in clinical applications.
Collapse
Affiliation(s)
- Weisong Zhao
- Human Anatomy Laboratory, School of Basic Medicine, Xinxiang Medical University, Xinxiang, Henan 453003, P.R. China
| | - Man Dong
- Department of Medicine, The Third Affiliated Hospital of Xinxiang Medical University, Xinxiang, Henan 453003, P.R. China
| | - Jinru Pan
- Human Anatomy Laboratory, School of Basic Medicine, Xinxiang Medical University, Xinxiang, Henan 453003, P.R. China
| | - Yajie Wang
- Human Anatomy Laboratory, School of Basic Medicine, Xinxiang Medical University, Xinxiang, Henan 453003, P.R. China
| | - Jingyi Zhou
- Human Anatomy Laboratory, School of Basic Medicine, Xinxiang Medical University, Xinxiang, Henan 453003, P.R. China
| | - Jianjun Ma
- Human Anatomy Laboratory, School of Basic Medicine, Xinxiang Medical University, Xinxiang, Henan 453003, P.R. China
| | - Shaoyang Liu
- Department of Orthopedics, Shanghai Putuo District Central Hospital, Shanghai 200062, P.R. China
| |
Collapse
|
8
|
Lao C, Lawrenson R, Edwards M, Campbell I. Treatment and survival of Asian women diagnosed with breast cancer in New Zealand. Breast Cancer Res Treat 2019; 177:497-505. [DOI: 10.1007/s10549-019-05310-z] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/27/2019] [Accepted: 05/29/2019] [Indexed: 12/24/2022]
|
9
|
Liu LH, Tian QQ, Liu J, Zhou Y, Yong H. Upregulation of hsa_circ_0136666 contributes to breast cancer progression by sponging miR-1299 and targeting CDK6. J Cell Biochem 2019; 120:12684-12693. [PMID: 30993801 DOI: 10.1002/jcb.28536] [Citation(s) in RCA: 28] [Impact Index Per Article: 5.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/22/2018] [Revised: 01/10/2019] [Accepted: 01/14/2019] [Indexed: 01/03/2023]
Abstract
Circular RNAs (circRNAs) can participate in multiple cancers, including breast cancer. Increasing circRNAs are recognized in various cancers because of the high-throughput sequencing. However, the potential physiological effect of hsa_circ_0136666 in breast cancer progression is unknown. In our study, the biological role of hsa_circ_0136666 in breast cancer development was studied. It was displayed that hsa_circ_0136666 was greatly increased in breast cancer. In addition, overexpression of hsa_circ_0136666 was able to promote Michigan Cancer Foundation-7 (MCF7) and BT474 cell proliferation and triggered cell cycle in G2/M phase. microRNA plays critical role in tumor development and they can act as direct targets of circRNAs. miR-1299 has been implicated as a famous tumor suppressor in many cancers. Here, miR-1299 was predicted as the target of hsa_circ_0136666. Meanwhile, its Upregulation repressed breast cancer proliferation, migration and invasion capacity, which could be reversed by the increase of hsa_circ_0136666. Furthermore, Cyclin-dependent kinase 6 (CDK6) was speculated as the downstream target of miR-1299. In MCF7 and BT474 cells, CDK6 was greatly overexpressed and it was shown that CDK6 contributed a lot to breast cancer progression. Subsequently, it was implied that hsa_circ_0136666 could modulate CDK6 levels positively in vitro. In conclusion, it was revealed that Upregulation of hsa_circ_0136666 promoted breast cancer progression by sponging miR-1299 and targeting CDK6.
Collapse
Affiliation(s)
- Li-Hong Liu
- Department of Pathology, The Central Hospital of Wuhan, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
| | - Qing-Qing Tian
- Department of Pathology, The Central Hospital of Wuhan, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
| | - Juan Liu
- Huai'an Second People's Hospital and The Affiliated Huai'an Hospital of Xuzhou Medical University, Huai'an, China
| | - Yong Zhou
- Department of Breast Surgery, The Central Hospital of Enshi Autonomous Prefecture, Enshi Clinical College of Wuhan University, Enshi, Hubei, China
| | - Hongmei Yong
- Department of Oncology, Huai'an Second People's Hospital and The Affiliated Huai'an Hospital of Xuzhou Medical University, 62 South Huaihai Rode, Huai'an, China
| |
Collapse
|
10
|
Rayne S, Schnippel K, Grover S, Fearnhead K, Kruger D, Benn C, Firnhaber C. Unraveling the South African Breast Cancer Story: The Relationship of Patients, Delay to Diagnosis, and Tumor Biology With Stage at Presentation in an Urban Setting. J Surg Res 2018; 235:181-189. [PMID: 30691793 DOI: 10.1016/j.jss.2018.09.087] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/20/2018] [Revised: 07/13/2018] [Accepted: 09/28/2018] [Indexed: 12/16/2022]
Abstract
BACKGROUND Adverse outcomes from breast cancer disproportionately affect women in sub-Saharan Africa, with delay the most studied contribution to advanced stage at presentation. However, tumor molecular biology and its contribution to advanced stage are yet to be explored. MATERIALS AND METHODS Patients newly diagnosed with breast cancer in a South African tertiary breast center completed a questionnaire and file review concerning socioeconomics, delay to care, stage at presentation, and molecular characteristics. Logistic regression was done to determine the relative risk of advanced stage presentation. RESULTS Advanced stage was present in 70.1% (n = 162) of the 231 participants, with 55.8% stage III (n = 129) and 32% (n = 72) having a T4 tumor. The median age was 56 y with 21.6% (n = 47) aged <45 y. Most common subtype was luminal B (57.7%, n = 128) followed by luminal A (21.6%, n = 48), triple negative (13.9%, n = 31), and HER2 positive (6.7%, n = 15). Lobular cancer (incidence risk ratio [IRR], 1.29; 95% confidence interval [CI], 1.03-1.62), high grade and intermediate grade tumors (IRR, 1.90; 95% CI, 1.15-3.13 and IRR, 1.95; 95% CI, 1.18-3.22, respectively), high Ki67 proliferation index (IRR, 1.30; 95% CI, 1.02-1.66), and HER2 overexpression (IRR, 1.32; 95% CI, 1.12-1.55) were more likely to present with advanced disease, as were luminal B (HER2+) cancers (adjusted IRR [aIRR], 1.46; 95% CI, 1.10-1.95). Although on univariate analysis Black and young participants were both more likely to have advanced stage (IRR, 1.23; 95% CI, 1.01-1.49 and IRR, 1.25; 95% CI, 1.04-1.51, respectively), in multivariate analysis controlling for tumor biology and delay, these were no longer significant (aIRR, 1.12; 95% CI, 0.91-1.37 and aIRR, 1.17; 95% CI, 0.94-1.48, respectively). CONCLUSIONS Tumor biology has a compelling role in the etiology of advanced-stage disease irrespective of socioeconomic factors. Accurate pathologic assessment is important in planning breast cancer care in Africa.
Collapse
Affiliation(s)
- Sarah Rayne
- Department of Surgery, Helen Joseph Hospital, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.
| | - Kathryn Schnippel
- Health Economics Unit, School of Public Health and Family Medicine, Faculty of Health Sciences, University of Cape Town, South Africa
| | - Surbhi Grover
- Department of Radiation Oncology, University of Pennsylvania, Philadelphia, Princess Marina Hospital, Gaborone, Botswana, Botswana-UPENN Partnership, Gaborone, Botswana
| | - Kirstin Fearnhead
- Department of Anatomical Pathology, National Health Laboratory Services, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa
| | - Deirdre Kruger
- Department of Surgery, Helen Joseph Hospital, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa
| | - Carol Benn
- Department of Surgery, Helen Joseph Hospital, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa
| | - Cynthia Firnhaber
- Clinical HIV Research Unit, Department of Internal Medicine, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa
| |
Collapse
|
11
|
Liu W, Wu J, Shi G, Yue X, Liu D, Zhang Q. Aberrant promoter methylation of PCDH10 as a potential diagnostic and prognostic biomarker for patients with breast cancer. Oncol Lett 2018; 16:4462-4470. [PMID: 30214581 PMCID: PMC6126325 DOI: 10.3892/ol.2018.9214] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/21/2018] [Accepted: 06/07/2018] [Indexed: 12/15/2022] Open
Abstract
Protocadherin-10 (PCDH10) is a tumor suppressor gene. Its expression level is downregulated by promoter methylation in certain types of human tumors. The aim of the present study was to examine the expression level and promoter methylation status of PCDH10 in breast cancer cells and to evaluate the association of PCDH10 methylation and tumor progression and prognosis. MethyLight was used to detect the methylation status of PCDH10 in breast cancer tissues and healthy breast tissues. Reverse transcription-quantitative polymerase chain reaction was used to assess the mRNA expression level of PCDH10, as well as to evaluate the association between PCDH10 methylation and clinicopathological features, along with patients' overall survival (OS). PCDH10 5'-C-phosphate-G-3' (CpG) methylated sites were identified in tumor tissues and matched healthy tissues (n=392). Tumor tissues and matched healthy tissues exhibited identifiable PCR results, with PCDH10 gene promoter methylation identified in ductal carcinoma in situ (66%), invasive ductal carcinoma (82%), invasive ductal carcinoma with lymph node metastasis (85.32%) and hereditary breast cancer tissues (72.37%). PCDH10 mRNA expression was significantly decreased in breast cancer tissues compared with healthy breast tissues (P=0.032). PCDH10 methylation was associated with tumor size (P=0.004), but not associated with other clinical factors. Survival analysis revealed that the patients exhibiting methylated-PCDH10 had significantly poorer OS times than patients exhibiting unmethylated-PCDH10 (P<0.0001). Receiver operating characteristic analysis indicated a sensitivity of 75%, a specificity of 62.5%, and an area under the curve of 0.682 for PCDH10. Additionally, the results of the present study indicated that PCDH10 methylation status may be a useful diagnostic and prognostic evaluation biomarker for breast cancer. The results suggested that PCDH10 methylation is a common occurrence in primary breast cancer and is associated with poor survival rates among patients with breast cancer.
Collapse
Affiliation(s)
- Wentao Liu
- Department of Medical Oncology, Harbin Medical University Cancer Hospital, Harbin, Heilongjiang 150081, P.R. China
| | - Jin Wu
- Department of Medical Oncology, Harbin Medical University Cancer Hospital, Harbin, Heilongjiang 150081, P.R. China
| | - Guangyue Shi
- Department of Medical Oncology, Harbin Medical University Cancer Hospital, Harbin, Heilongjiang 150081, P.R. China
| | - Xiaolong Yue
- Department of Medical Oncology, Harbin Medical University Cancer Hospital, Harbin, Heilongjiang 150081, P.R. China
| | - Dan Liu
- Department of Medical Oncology, Harbin Medical University Cancer Hospital, Harbin, Heilongjiang 150081, P.R. China
| | - Qingyuan Zhang
- Department of Medical Oncology, Harbin Medical University Cancer Hospital, Harbin, Heilongjiang 150081, P.R. China
| |
Collapse
|
12
|
Tin Tin S, Elwood JM, Brown C, Sarfati D, Campbell I, Scott N, Ramsaroop R, Seneviratne S, Harvey V, Lawrenson R. Ethnic disparities in breast cancer survival in New Zealand: which factors contribute? BMC Cancer 2018; 18:58. [PMID: 29310606 PMCID: PMC5759270 DOI: 10.1186/s12885-017-3797-0] [Citation(s) in RCA: 22] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/01/2016] [Accepted: 11/17/2017] [Indexed: 11/24/2022] Open
Abstract
Background New Zealand has major ethnic disparities in breast cancer survival with Māori (indigenous people) and Pacific women (immigrants or descended from immigrants from Pacific Islands) faring much worse than other ethnic groups. This paper identified underlying factors and assessed their relative contribution to this risk differential. Methods This study involved all women who were diagnosed with primary invasive breast cancer in two health regions, covering about 40% of the national population, between January 2000 and June 2014. Māori and Pacific patients were compared with other ethnic groups in terms of demographics, mode of diagnosis, disease factors and treatment factors. Cox regression modelling was performed with stepwise adjustments, and hazards of excess mortality from breast cancer for Māori and Pacific patients were assessed. Results Of the 13,657 patients who were included in this analysis, 1281 (9.4%) were Māori, and 897 (6.6%) were Pacific women. Compared to other ethnic groups, they were younger, more likely to reside in deprived neighbourhoods and to have co-morbidities, and less likely to be diagnosed through screening and with early stage cancer, to be treated in a private care facility, to receive timely cancer treatment, and to receive breast conserving surgery. They had a higher risk of excess mortality from breast cancer (age and year of diagnosis adjusted hazard ratio: 1.76; 95% CI: 1.51–2.04 for Māori and 1.97; 95% CI: 1.67–2.32 for Pacific women), of which 75% and 99% respectively were explained by baseline differences. The most important contributor was late stage at diagnosis. Other contributors included neighbourhood deprivation, mode of diagnosis, type of health care facility where primary cancer treatment was undertaken and type of loco-regional therapy. Conclusions Late diagnosis, deprivation and differential access to and quality of cancer care services were the key contributors to ethnic disparities in breast cancer survival in New Zealand. Our findings underscore the need for a greater equity focus along the breast cancer care pathway, with an emphasis on improving access to early diagnosis for Māori and Pacific women. Electronic supplementary material The online version of this article (10.1186/s12885-017-3797-0) contains supplementary material, which is available to authorized users.
Collapse
Affiliation(s)
- Sandar Tin Tin
- Section of Epidemiology and Biostatistics, School of Population Health, The University of Auckland, Auckland, New Zealand.
| | - J Mark Elwood
- Section of Epidemiology and Biostatistics, School of Population Health, The University of Auckland, Auckland, New Zealand
| | - Charis Brown
- SMART Marketing and Research, Hamilton, New Zealand
| | - Diana Sarfati
- Department of Public Health, The University of Otago, Wellington, New Zealand
| | - Ian Campbell
- Waikato Clinical Campus, The University of Auckland, Hamilton, New Zealand.,Waikato District Health Board, Hamilton, New Zealand
| | - Nina Scott
- Waikato District Health Board, Hamilton, New Zealand
| | - Reena Ramsaroop
- Surgical Pathology Department, Waitemata District Health Board, Auckland, New Zealand
| | | | - Vernon Harvey
- Auckland District Health Board, Auckland, New Zealand
| | - Ross Lawrenson
- National Institute of Demographic and Economic Analysis, The University of Waikato, Hamilton, New Zealand.,Waikato District Health Board, Hamilton, New Zealand
| |
Collapse
|
13
|
Lawrenson R, Lao C, Campbell I, Harvey V, Seneviratne S, Edwards M, Elwood M, Scott N, Kidd J, Sarfati D, Kuper-Hommel M. Treatment and survival disparities by ethnicity in New Zealand women with stage I–III breast cancer tumour subtypes. Cancer Causes Control 2017; 28:1417-1427. [DOI: 10.1007/s10552-017-0969-9] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/31/2017] [Accepted: 09/21/2017] [Indexed: 12/16/2022]
|
14
|
Tang YY, Zhao P, Zou TN, Duan JJ, Zhi R, Yang SY, Yang DC, Wang XL. Circular RNA hsa_circ_0001982 Promotes Breast Cancer Cell Carcinogenesis Through Decreasing miR-143. DNA Cell Biol 2017; 36:901-908. [PMID: 28933584 DOI: 10.1089/dna.2017.3862] [Citation(s) in RCA: 128] [Impact Index Per Article: 18.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022] Open
Abstract
Circular RNAs (circRNAs) are a type of noncoding RNAs generated from back-splicing, which have been verified to mediate multiple tumorigenesis. With the development of high-throughput sequencing, massive circRNAs are discovered in tumorous tissue. However, the potential physiological effect of circRNAs in breast cancer is still unknown. The purpose of this study is to investigate the expression profile of circRNA in breast cancer tissue and explore the in-depth regulatory mechanism in breast cancer tumorigenesis. In the present study, we screened the circRNA expression profiles in breast cancer tissue using circRNA microarray analysis. Totally 1705 circRNAs were identified to be significantly aberrant. Among these dysregulated circRNAs, hsa_circ_0001982 was markedly overexpressed in breast cancer tissue and cell lines. Bioinformatics analysis predicted that miR-143 acted as target of hsa_circ_0001982, which was confirmed by Dual-luciferase reporter assay. Loss-of-function and rescue experiments revealed that hsa_circ_0001982 knockdown suppressed breast cancer cell proliferation and invasion and induced apoptosis by targeting miR-143. In summary, our study preliminarily investigates the circRNA expression in breast cancer tissue and explores the role of competing endogenous RNA (ceRNA) mechanism in the progression, providing a novel insight for breast cancer tumorigenesis.
Collapse
Affiliation(s)
- Yi-Yin Tang
- The First Mammary Surgical Department, The Third Affiliated Hospital of Kunming Medical University and Tumor Hospital of Yunnan Province , Kunming, China
| | - Ping Zhao
- The First Mammary Surgical Department, The Third Affiliated Hospital of Kunming Medical University and Tumor Hospital of Yunnan Province , Kunming, China
| | - Tian-Ning Zou
- The First Mammary Surgical Department, The Third Affiliated Hospital of Kunming Medical University and Tumor Hospital of Yunnan Province , Kunming, China
| | - Jia-Jun Duan
- The First Mammary Surgical Department, The Third Affiliated Hospital of Kunming Medical University and Tumor Hospital of Yunnan Province , Kunming, China
| | - Rong Zhi
- The First Mammary Surgical Department, The Third Affiliated Hospital of Kunming Medical University and Tumor Hospital of Yunnan Province , Kunming, China
| | - Si-Yuan Yang
- The First Mammary Surgical Department, The Third Affiliated Hospital of Kunming Medical University and Tumor Hospital of Yunnan Province , Kunming, China
| | - De-Chun Yang
- The First Mammary Surgical Department, The Third Affiliated Hospital of Kunming Medical University and Tumor Hospital of Yunnan Province , Kunming, China
| | - Xiao-Li Wang
- The First Mammary Surgical Department, The Third Affiliated Hospital of Kunming Medical University and Tumor Hospital of Yunnan Province , Kunming, China
| |
Collapse
|
15
|
Lawrenson R, Lao C, Campbell I, Harvey V, Brown C, Seneviratne S, Edwards M, Elwood M, Kuper-Hommel M. The use of trastuzumab in New Zealand women with breast cancer. Asia Pac J Clin Oncol 2017; 14:e152-e160. [DOI: 10.1111/ajco.12766] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/18/2017] [Accepted: 06/11/2017] [Indexed: 11/29/2022]
|
16
|
Bhandari V, Boutros PC. Comparing continuous and discrete analyses of breast cancer survival information. Genomics 2016; 108:78-83. [DOI: 10.1016/j.ygeno.2016.06.002] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/29/2016] [Revised: 05/25/2016] [Accepted: 06/11/2016] [Indexed: 10/21/2022]
|
17
|
Lawrenson R, Seneviratne S, Scott N, Peni T, Brown C, Campbell I. Breast cancer inequities between Māori and non-Māori women in Aotearoa/New Zealand. Eur J Cancer Care (Engl) 2016; 25:225-30. [DOI: 10.1111/ecc.12473] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 01/27/2016] [Indexed: 11/30/2022]
Affiliation(s)
- R. Lawrenson
- Waikato Clinical Campus; The University of Auckland; Hamilton New Zealand
| | - S. Seneviratne
- Department of Surgery; Faculty of Medicine; National Hospital of Sri Lanka; University of Colombo; Colombo Sri Lanka
| | - N. Scott
- Te Puna Oranga; Waikato District Health Board; Hamilton New Zealand
| | - T. Peni
- Waikato Clinical Campus; The University of Auckland; Hamilton New Zealand
| | - C. Brown
- Waikato Clinical Campus; The University of Auckland; Hamilton New Zealand
| | - I. Campbell
- Waikato Clinical Campus; The University of Auckland; Hamilton New Zealand
| |
Collapse
|